Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 81Colorectal Neoplasms 39Stomach Neoplasms 17Carcinoma, Non-Small-Cell Lung 15Liver Neoplasms 14Neoplasms 11Melanoma 11Carcinoma, Renal Cell 11Esophageal Neoplasms 10Pancreatic Neoplasms 9Carcinoma, Transitional Cell 8Breast Neoplasms 8Uterine Cervical Neoplasms 7Triple Negative Breast Neoplasms 7Squamous Cell Carcinoma of Head and Neck 7Small Cell Lung Carcinoma 7Ovarian Neoplasms 7Head and Neck Neoplasms 7Cholangiocarcinoma 7Rectal Neoplasms 6Neoplasm Metastasis 6Colonic Neoplasms 6Urinary Bladder Neoplasms 5Gastrointestinal Neoplasms 5Carcinoma, Merkel Cell 5Biliary Tract Neoplasms 5Prostatic Neoplasms 4Sarcoma 3Lung Neoplasms 3Gallbladder Neoplasms 3

Interventions

atezolizumab 1Tomography, X-Ray Computed 1Metformin 1Liquid Biopsy 1Endosonography 1Blood Specimen Collection 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fatty Liver × atezolizumab × Gastrointestinal × Clear all
NCT06096779 2026-06-01

Kirros

Genentech, Inc.

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Digestive System Neoplasms, Fatty Liver, Fibrosis, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡